LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

Search

Pulse Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

15.21 -0.98

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.1

Max

15.84

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.4M

-19M

Pelnas, tenkantis vienai akcijai

-0.28

Pelno marža

-2,018.63

Darbuotojai

75

EBITDA

-857K

-19M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+42.3% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

137M

1.1B

Ankstesnė atidarymo kaina

16.19

Ankstesnė uždarymo kaina

15.21

Naujienos nuotaikos

By Acuity

67%

33%

329 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Pulse Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-11 23:59; UTC

Uždarbis

Singtel's 1st Half Net Profit Surges

2025-11-11 22:23; UTC

Įsigijimai, susijungimai, perėmimai

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

2025-11-11 22:21; UTC

Uždarbis

Aristocrat Boosts Dividend as Annual Profit Rises 12%

2025-11-11 23:52; UTC

Rinkos pokalbiai

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

2025-11-11 23:44; UTC

Uždarbis

Singtel's 1H Net Profit Surges

2025-11-11 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

2025-11-11 23:18; UTC

Uždarbis

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

2025-11-11 23:15; UTC

Uždarbis

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

2025-11-11 23:14; UTC

Uždarbis

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

2025-11-11 23:12; UTC

Uždarbis

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

2025-11-11 23:11; UTC

Uždarbis

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

2025-11-11 23:10; UTC

Uždarbis

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

2025-11-11 23:04; UTC

Rinkos pokalbiai

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

2025-11-11 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-11-11 21:50; UTC

Rinkos pokalbiai
Uždarbis

Health Care Roundup: Market Talk

2025-11-11 21:46; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

2025-11-11 21:41; UTC

Uždarbis

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

2025-11-11 21:40; UTC

Uždarbis

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

2025-11-11 21:39; UTC

Uždarbis

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

2025-11-11 21:39; UTC

Uždarbis

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

2025-11-11 21:39; UTC

Uždarbis

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

2025-11-11 21:38; UTC

Uždarbis

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

2025-11-11 21:38; UTC

Uždarbis

Aristocrat: Final Dividend 49 Australian Cents/Share

2025-11-11 21:37; UTC

Uždarbis

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

2025-11-11 21:36; UTC

Uždarbis

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

2025-11-11 21:35; UTC

Uždarbis

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

2025-11-11 21:35; UTC

Uždarbis

Alcon 3Q Adj EPS 79c >ALC

2025-11-11 21:35; UTC

Uždarbis

Alcon 3Q Rev $2.61B >ALC.EB

2025-11-11 21:35; UTC

Uždarbis

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

2025-11-11 21:35; UTC

Uždarbis

Alcon 3Q EPS 48c >ALC.EB

Akcijų palyginimas

Kainos pokytis

Pulse Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

42.3% į viršų

12 mėnesių prognozė

Vidutinis 22 USD  42.3%

Aukščiausias 22 USD

Žemiausias 22 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pulse Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

16.59 / 17.17Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

329 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
help-icon Live chat